BioSpace News Archive

Exelixis, Inc. and Cybrexa Therapeutics announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12, a clinical-stage, first-in-class peptide-drug conjugate that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter financial results on Wednesday, November 9, 2022.

Focal Medical, Inc., a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative local drug delivery technology platform, announced the appointment of Michael Aldridge as the Company’s new Chief Executive Officer.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK) today announced it will report third quarter 2022 financial results and provide a general business overview on Tuesday, November 8, 2022.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the appointment of Richard Rodgers, MBA to its board as an independent director.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their collaboration with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX).

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.

PRNewswire -- I Peace, Inc. announced that the company has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace has been providing

Avista Capital Partners, a leading private equity firm focused exclusively on healthcare, announced its acquisition of Taconic Biosciences, a leading provider of genetically engineered research models and related services, from H.I.G. Capital.

Physicians at Tampa General Hospital’s emergency department are the first in the nation, outside of a clinical trial setting, to use an FDA-cleared rapid blood test to successfully evaluate patients who are 18 and older with mild traumatic brain injury, including concussions.